Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Illumina Laboratory Services, |
RCV001104787 | SCV001261674 | uncertain significance | Usher syndrome type 1 | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
| Labcorp Genetics |
RCV001223316 | SCV001395458 | likely benign | not provided | 2024-12-02 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV001223316 | SCV003803607 | uncertain significance | not provided | 2023-04-25 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Department of Pathology and Laboratory Medicine, |
RCV001223316 | SCV001553105 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The PCDH15 p.Ser1817Phe variant was not identified in the literature nor was it identified in ClinVar, Cosmic or LOVD 3.0. The variant was identified in dbSNP (ID: rs140047846) and in control databases in 70 of 282722 chromosomes at a frequency of 0.000248 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (Finnish) in 19 of 25118 chromosomes (freq: 0.000756), Other in 4 of 7224 chromosomes (freq: 0.000554) and European (non-Finnish) in 47 of 129064 chromosomes (freq: 0.000364); it was not observed in the African, Latino, Ashkenazi Jewish, East Asian and South Asian populations. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Ser1817 residue is conserved in mammals but not distantly related organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. | |
| Natera, |
RCV001833703 | SCV002083298 | uncertain significance | Usher syndrome type 1F | 2020-02-13 | no assertion criteria provided | clinical testing |